Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Salil S Ghamande,Zachary Klaassen,Christopher J.D Wallis

doi:10.1016/j.eururo.2023.04.031

Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Salil S Ghamande, Zachary Klaassen + Show 1 more

https://doi.org/10.1016/j.eururo.2023.04.031

Copy DOI

Journal: European Urology	Publication Date: May 12, 2023
Citations: 1

Affiliation: Augusta University, University of Toronto, Mount Sinai Hospital

#Metastatic Hormone-sensitive Prostate Cancer #Androgen-deprivation Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: European Urology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.